Compare Humana Inc (HUM) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs UiPath Inc — how do they compare? Humana Inc trades at $405.65 (market cap $47.81B), while UiPath Inc trades at $12 (market cap $6.30B). The key difference: Humana Inc is far larger — about 7.6× UiPath Inc's market cap, and Humana Inc pays a 0.89% dividend while UiPath Inc pays none. Which is the better fit depends on your goals.
| HUM | PATH | |
|---|---|---|
Market Cap | $47.81B | $6.30B |
Sector | Health | Technology |
52-Week High | $409.42 | $19.29 |
52-Week Low | $163.67 | $9.38 |
Enterprise Value | $56.85B | $5.08B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $398.09, down 0.48% with a bullish technical signal from moving averages. The company shows strong revenue growth to $129.66B in 2025 but faces margin compression with net income margin declining to 0.82%. Recent earnings have consistently beaten expectations, and analyst sentiment is mixed with 34% buy ratings but a consensus price target of $354.33 below current levels.
The outlook suggests cautious optimism with Medicare Advantage expansion opportunities but significant margin pressure and regulatory risks. Key investment considerations include the company's ability to achieve its 3% Medicare Advantage margin target by 2028 while navigating increased healthcare utilization costs and competitive pressures in the insurance sector.
UiPath (PATH) trades at $12.26, up 0.91% today, with a bullish technical outlook and strong support at $12. The company shows improving fundamentals, with revenue growing to $1.43B in 2025 and a projected net profit of $327M in 2026. Recent news highlights AI partnerships and agentic automation growth, though Q1 2026 EPS missed expectations.
Outlook is cautiously optimistic with a consensus price target of $13.33, offering ~9% upside. Key opportunities include high gross margins and AI adoption, while risks involve execution on profitability and competitive pressures. Institutional sentiment is mixed with 25% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
